P. C. Brooks, S. Stromblad, R. Klemke, D. Visscher, F. H. Sarkar et al., Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin., Journal of Clinical Investigation, vol.96, issue.4, pp.1815-1837, 1995.
DOI : 10.1172/JCI118227

P. C. Brooks, Role of integrins in angiogenesis, European Journal of Cancer, vol.32, issue.14, pp.32-2423, 1996.
DOI : 10.1016/S0959-8049(96)00381-4

P. A. Burke, S. J. Denardo, L. A. Miers, K. R. Lamborn, S. Matzku et al., Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts, Cancer Res, issue.15, pp.62-4263, 2002.

P. Carmeliet, L. Moons, A. Luttun, V. Vincenti, V. Compernolle et al., Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions, Nature Medicine, vol.7, issue.5, pp.575-83, 2001.
DOI : 10.1038/87904

P. Carmeliet, Angiogenesis in health and disease, Nature Medicine, vol.9, issue.6, pp.653-60, 2003.
DOI : 10.1038/nm0603-653

S. Castel, R. Pagan, R. Garcia, R. P. Casaroli-marano, M. Reina et al., Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells, European Journal of Cell Biology, vol.79, issue.7, pp.79-502, 2000.
DOI : 10.1078/0171-9335-00067

S. Castel, R. Pagan, F. Mitjans, J. Piulats, S. Goodman et al., RGD peptides and monoclonal antibodies, antagonists of alpha(v)integrin , enter the cells by independent endocytic pathways, Lab Invest, issue.12, pp.81-1615, 2001.

Z. Chang, A. Choon, and A. Friedl, Endostatin Binds to Blood Vessels in Situ. Independent of Heparan Sulfate and Does Not Compete for Fibroblast Growth Factor-2 Binding, The American Journal of Pathology, vol.155, issue.1, pp.71-77, 1999.
DOI : 10.1016/S0002-9440(10)65101-2

S. Chatterjee, K. H. Brite, and A. Matsumura, Induction of apoptosis of integrinexpressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides, Clin Cancer Res, vol.7, issue.10, pp.3006-3017, 2001.

N. Chattopadhyay, A. Mitra, E. Frei, and A. Chatterjee, Human cervical tumor cell (SiHa) surface alphavbeta3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity, J Cancer Res Clin Oncol, issue.11, pp.127-653, 2001.

C. , N. Chatterjee, and A. , Studies on the expression of alpha(v)beta3 integrin receptors in non-malignant and malignant human cervical tumor tissues, J Exp Clin Cancer Res, vol.20, issue.2, pp.269-75, 2001.

Y. X. Chen, X. M. Xu, S. G. Hong, J. G. Chen, N. F. Liu et al., RGD-tachyplesin inhibits tumor growth, Cancer Res, issue.6, pp.61-2434, 2001.

X. Chen, M. Tohme, R. Park, Y. Hou, J. R. Bading et al., Micro-PET Imaging of ??<SUB>v</SUB>??<SUB>3</SUB>-Integrin Expression with <SUP>18</SUP>F-Labeled Dimeric RGD Peptide, Molecular Imaging, vol.3, issue.2, pp.96-104, 2004.
DOI : 10.1162/1535350041464892

C. , X. Park, R. Hou, Y. Khankaldyyan, V. Gonzales-gomez et al., MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide, Eur J Nucl Med Mol Imaging, issue.8, pp.31-1081, 2004.

C. , X. Park, R. Shahinian, A. H. Bading, J. R. Conti et al., Pharmacokinetics and tumor retention of (125)I-labeled RGD peptide are improved by PEGylation, Nucl Med Biol, issue.1, pp.31-42, 2004.

C. , X. Park, R. Tohme, M. Shahinian, A. H. Bading et al., MicroPET and Autoradiographic Imaging of Breast Cancer alpha(v)-Integrin Expression Using (18)F-and (64)Cu-Labeled RGD Peptide, Bioconjug Chem, vol.15, issue.1, pp.41-50, 2004.

H. Bading, J. R. Moats, R. Laug, W. E. Conti, and P. S. , 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis, Nucl Med Biol, issue.2, pp.31-179, 2004.

X. Chen, E. Sievers, Y. Hou, R. Park, M. Tohme et al., Integrin ????3-Targeted Imaging of Lung Cancer, Neoplasia, vol.7, issue.3, pp.271-280, 2005.
DOI : 10.1593/neo.04538

X. Chen, R. Park, V. Khankaldyyan, I. Gonzales-gomez, M. Tohme et al., Longitudinal MicroPET Imaging of Brain Tumor Growth with F-18-labeled RGD Peptide, Molecular Imaging and Biology, vol.31, issue.Suppl., pp.9-15, 2006.
DOI : 10.1007/s11307-005-0024-1

D. A. Cheresh, Structural and biologic properties of integrin-mediated cell adhesion, Clin Lab Med, vol.12, issue.2, pp.217-253, 1992.

D. Citrin, T. Scott, M. Sproull, C. Menard, P. J. Tofilon et al., In vivo tumor imaging using a near-infrared???labeled endostatin molecule, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.2, pp.536-577, 2004.
DOI : 10.1016/j.ijrobp.2003.09.068

E. A. Clark and J. S. Brugge, Integrins and signal transduction pathways: the road taken, Science, vol.268, issue.5208, pp.233-242, 1995.
DOI : 10.1126/science.7716514

P. Clezardin, Recent insights into the role of integrins in cancer metastasis, Cellular and Molecular Life Sciences (CMLS), vol.54, issue.6, pp.541-549, 1998.
DOI : 10.1007/s000180050182

G. Conforti, C. Dominguez-jimenez, A. Zanetti, M. A. Gimbrone, . Jr et al., Human endothelial cells express integrin receptors on the luminal aspect of their membrane, Blood, vol.80, issue.2, pp.437-483, 1992.

. Cilengitide, a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours, Eur J Cancer, vol.39, issue.7, pp.917-943, 2003.

F. A. Eskens, Angiogenesis inhibitors in clinical development; where are we now and where are we going?, British Journal of Cancer, vol.90, issue.1, pp.1-7, 2004.
DOI : 10.1038/sj.bjc.6601401

G. I. Evan and K. H. Vousden, Proliferation, cell cycle and apoptosis in cancer, Nature, issue.6835, pp.411-342, 2001.

M. Fani, D. Psimadas, C. Zikos, S. Xanthopoulos, G. K. Loudos et al., Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis, Anticancer Res, issue.1A, pp.26-431, 2006.

J. J. Feige and S. Bailly, [Molecular bases of angiogenesis], Bull Acad Natl Med, vol.184, issue.3, pp.537-581, 2000.

B. Felding-habermann, B. M. Mueller, C. A. Romerdahl, and D. A. Cheresh, Involvement of integrin alpha V gene expression in human melanoma tumorigenicity., Journal of Clinical Investigation, vol.89, issue.6, pp.2018-2040, 1992.
DOI : 10.1172/JCI115811

B. Felding-habermann, E. Fransvea, T. E. O-'toole, L. Manzuk, B. Faha et al., Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells, Clinical and Experimental Metastasis, vol.19, issue.5, pp.427-463, 2002.
DOI : 10.1023/A:1016377114119

N. Ferrara and W. J. Henzel, Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells, Biochemical and Biophysical Research Communications, vol.161, issue.2, pp.851-859, 1989.
DOI : 10.1016/0006-291X(89)92678-8

N. Ferrara, H. P. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nature Medicine, vol.9, issue.6, pp.669-76, 2003.
DOI : 10.1038/nm0603-669

J. B. Fleming and R. A. Brekken, Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer, Journal of Cellular Biochemistry, vol.99, issue.3, pp.492-501, 2003.
DOI : 10.1002/jcb.10644

J. Folkman, Tumor angiogenesis: therapeutic implications, N Engl J Med, vol.285, issue.21, pp.1182-1188, 1971.

J. Folkman, What is the role of endothelial cells in angiogenesis?, Lab Invest, vol.51, issue.6, pp.601-605, 1984.

J. Folkman, What Is the Evidence That Tumors Are Angiogenesis Dependent?, JNCI Journal of the National Cancer Institute, vol.82, issue.1, pp.4-6, 1990.
DOI : 10.1093/jnci/82.1.4

J. Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease, Nature Medicine, vol.326, issue.1, pp.27-31, 1995.
DOI : 10.1038/359845a0

P. Fons, B. Malavaud, L. Venat, and J. Plouet, [Anti-angiogenesis strategies in cancer], Bull Acad Natl Med, vol.184, issue.3, pp.579-86, 2000.

W. Guo and F. G. Giancotti, Integrin signalling during tumour progression, Nature Reviews Molecular Cell Biology, vol.14, issue.10, pp.816-842, 2004.
DOI : 10.1101/GAD.903001

J. C. Gutheil, T. N. Campbell, P. R. Pierce, J. D. Watkins, W. D. Huse et al., Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3, Clin Cancer Res, vol.6, issue.8, pp.3056-61, 2000.

D. Hanahan and J. Folkman, Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis, Cell, vol.86, issue.3, pp.353-64, 1996.
DOI : 10.1016/S0092-8674(00)80108-7

D. Hanahan and R. A. Weinberg, The hallmarks of cancer, pp.57-70, 2000.

T. D. Harris, S. Kalogeropoulos, T. Nguyen, S. Liu, J. Bartis et al., Receptor Antagonists for Tumor Imaging and Radiotherapy, Cancer Biotherapy & Radiopharmaceuticals, vol.18, issue.4, pp.627-668, 2003.
DOI : 10.1089/108497803322287727

J. Hasan, R. Byers, and G. C. Jayson, Intra-tumoural microvessel density in human solid tumours, British Journal of Cancer, vol.5, issue.10, pp.1566-77, 2002.
DOI : 10.1038/sj.bjc.6600315

K. Hata and K. Miyazaki, Color Doppler imaging and angiogenesis in ovarian tumors, Medical Electron Microscopy, vol.36, issue.3, pp.127-157, 2003.
DOI : 10.1007/s00795-001-0155-7

R. Haubner, H. J. Wester, U. Reuning, R. Senekowitsch-schmidtke, B. Diefenbach et al., Radiolabeled alpha(v)beta(3) integrin antagonists: A new class of tracers for tumor targeting, J Nucl Med, issue.6, pp.40-1061, 1999.

R. Haubner, H. J. Wester, W. A. Weber, C. Mang, S. I. Ziegler et al., Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography, Cancer Res, issue.5, pp.61-1781, 2001.

R. Haubner, F. Bruchertseifer, M. Bock, H. Kessler, M. Schwaiger et al., Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression, Nuklearmedizin, vol.43, issue.1, pp.26-32, 2004.

R. Haubner, W. A. Weber, A. J. Beer, E. Vabuliene, D. Reim et al., Noninvasive Visualization of the Activated ??v??3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD, PLoS Medicine, vol.6, issue.3, p.70, 2005.
DOI : 10.1371/journal.pmed.0020070.sd002

E. G. Hayman, M. D. Pierschbacher, and E. Ruoslahti, Detachment of cells from culture substrate by soluble fibronectin peptides, The Journal of Cell Biology, vol.100, issue.6, pp.1948-54, 1985.
DOI : 10.1083/jcb.100.6.1948

J. Holash, S. J. Wiegand, and G. D. Yancopoulos, New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF, Oncogene, vol.18, issue.38, pp.5356-62, 1999.
DOI : 10.1038/sj.onc.1203035

J. D. Hood, M. Bednarski, R. Frausto, S. Guccione, R. A. Reisfeld et al., Tumor Regression by Targeted Gene Delivery to the Neovasculature, Science, vol.296, issue.5577, pp.296-2404, 2002.
DOI : 10.1126/science.1070200

M. J. Humphries, Insights into integrin-ligand binding and activation from the first crystal structure, Arthritis Research, vol.4, issue.Suppl 3, pp.69-78, 2002.
DOI : 10.1186/ar563

J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, issue.23, pp.350-2335, 2004.

R. O. Hynes, A reevaluation of integrins as regulators of angiogenesis, Nature Medicine, vol.4, issue.9, pp.918-939, 2002.
DOI : 10.1038/nm0302-193

E. Iivanainen, V. M. Kahari, J. Heino, and K. Elenius, Endothelial cell???Matrix interactions, Microscopy Research and Technique, vol.60, issue.1, pp.13-22, 2003.
DOI : 10.1002/jemt.10238

T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell et al., Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts, The American Journal of Pathology, vol.165, issue.1, pp.35-52, 2004.
DOI : 10.1016/S0002-9440(10)63273-7

D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru et al., Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth, Nature, vol.348, issue.6301, pp.348-555, 1990.
DOI : 10.1038/348555a0

I. Iordanescu, C. Becker, B. Zetter, P. Dunning, and G. A. Taylor, Tumor Vascularity: Evaluation in a Murine Model with Contrast-enhanced Color Doppler US???Effect of Angiogenesis Inhibitors, Radiology, vol.222, issue.2, pp.460-467, 2002.
DOI : 10.1148/radiol.2222010660

R. K. Jain and L. L. Munn, Leaky vessels? Call Ang1!, Nature Medicine, vol.6, issue.2, pp.131-133, 2000.
DOI : 10.1038/72212

R. K. Jain, Molecular regulation of vessel maturation, Nature Medicine, vol.9, issue.6, pp.685-93, 2003.
DOI : 10.1038/nm0603-685

M. L. Janssen, W. J. Oyen, I. Dijkgraaf, L. F. Massuger, C. Frielink et al., Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model, Cancer Res, issue.21, pp.62-6146, 2002.

M. Janssen-b, W. J. Oyen, L. F. Massuger, C. Frielink, I. Dijkgraaf et al., Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting, Cancer Biotherapy & Radiopharmaceuticals, vol.17, issue.6, pp.17-641, 2002.
DOI : 10.1089/108497802320970244

G. C. Jayson, J. Zweit, A. Jackson, C. Mulatero, P. Julyan et al., Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies, JNCI Journal of the National Cancer Institute, vol.94, issue.19, pp.94-1484, 2002.
DOI : 10.1093/jnci/94.19.1484

A. Jekunen and K. Kairemo, Inhibition of angiogenesis at endothelial cell level, Microscopy Research and Technique, vol.60, issue.1, pp.85-97, 2003.
DOI : 10.1002/jemt.10247

H. Jin and J. Varner, Integrins: roles in cancer development and as treatment targets, British Journal of Cancer, vol.90, issue.3, pp.561-566, 2004.
DOI : 10.1038/sj.bjc.6601576

H. Joensuu and S. Dimitrijevic, Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours, Annals of Medicine, vol.20, issue.7, pp.451-456, 2001.
DOI : 10.2165/00003495-200060001-00004

A. John and G. Tuszynski, The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis, Pathology & Oncology Research, vol.22, issue.1, pp.14-23, 2001.
DOI : 10.1007/BF03032599

M. Kawaguchi, R. Hosotani, S. Ohishi, N. Fujii, S. S. Tulachan et al., A Novel Synthetic Arg-Gly-Asp-Containing Peptide Cyclo(-RGDf???V-) Is the Potent Inhibitor of Angiogenesis, Biochemical and Biophysical Research Communications, vol.288, issue.3, pp.711-718, 2001.
DOI : 10.1006/bbrc.2001.5809

J. S. Kerr, A. M. Slee, and S. A. Mousa, Small molecule ??v integrin antagonists: novel anticancer agents, Expert Opinion on Investigational Drugs, vol.10, issue.6, pp.1271-1280, 2000.
DOI : 10.1038/nm0598-623

R. Kerbel and J. Folkman, Clinical translation of angiogenesis inhibitors, Nature Reviews Cancer, vol.17, issue.10, pp.727-766, 2002.
DOI : 10.1038/nrc905

F. Kiessling, S. Greschus, M. P. Lichy, M. Bock, C. Fink et al., Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis, Nature Medicine, vol.210, issue.10, pp.10-1133, 2004.
DOI : 10.1038/nm1197-1222

T. Kilic, J. A. Alberta, P. R. Zdunek, M. Acar, P. Iannarelli et al., Intracranial inhibition of platelet-derived growth factormediated glioblastoma cell growth by an orally active kinase inhibitor of the 2- phenylaminopyrimidine class, Cancer Res, issue.18, pp.60-5143, 2000.

K. J. Kim, B. Li, J. Winer, M. Armanini, N. Gillett et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, vol.362, issue.6423, pp.362-841, 1993.
DOI : 10.1038/362841a0

D. R. Knighton, G. D. Phillips, and V. D. Fiegel, Wound Healing Angiogenesis, The Journal of Trauma: Injury, Infection, and Critical Care, vol.30, issue.12, pp.134-178, 1990.
DOI : 10.1097/00005373-199012001-00027

K. Koizumi, Y. Tsutsumi, H. Kamada, Y. Yoshioka, M. Watanabe et al., Incorporation of adult organ-derived endothelial cells into tumor blood vessel, Biochemical and Biophysical Research Communications, vol.306, issue.1, pp.219-243, 2003.
DOI : 10.1016/S0006-291X(03)00938-0

C. C. Kumar, Integrin &#945;v&#946;3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis, Current Drug Targets, vol.4, issue.2, pp.123-154, 2003.
DOI : 10.2174/1389450033346830

A. D. Laird, P. Vajkoczy, L. K. Shawver, A. Thurnher, C. Liang et al., SU6668 is a potent antiangiogenic and anti-tumor agent that induces regression of established tumors, Cancer Res, issue.15, pp.60-4152, 2000.

D. A. Lauffenburger and A. F. Horwitz, Cell Migration: A Physically Integrated Molecular Process, Cell, vol.84, issue.3, pp.359-69, 1996.
DOI : 10.1016/S0092-8674(00)81280-5

K. H. Lee, K. H. Jung, S. H. Song, D. H. Kim, B. C. Lee et al., Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs, J Nucl Med, vol.46, issue.3, pp.472-480, 2005.

B. Lelongt, P. Ronco, and R. Piedagnel, M??talloprot??ases matricielles : infid??lit??s ?? la matrice extracellulaire, m??decine/sciences, vol.18, issue.5, pp.519-540, 2002.
DOI : 10.1051/medsci/2002185519

X. Li, J. Regezi, F. P. Ross, S. Blystone, D. Ilic et al., Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro, J Cell Sci, pp.114-2665, 2001.

S. Li, M. Peck-radosavljevic, O. Kienast, J. Preitfellner, E. Havlik et al., Iodine- 123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma, Q J Nucl Med Mol Imaging, vol.48, issue.3, pp.198-206, 2004.

S. Liekens, E. De-clercq, and J. Neyts, Angiogenesis: regulators and clinical applications, Biochemical Pharmacology, vol.61, issue.3, pp.253-70, 2001.
DOI : 10.1016/S0006-2952(00)00529-3
URL : http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_eid=1-s2.0-S0006295200005293&originContentFamily=serial&_origin=article&_ts=1480639596&md5=e6c6a26113740e5c655cb85e76842386

B. R. Line, A. Mitra, A. Nan, and H. Ghandehari, Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates, J Nucl Med, vol.46, issue.9, pp.1552-60, 2005.

Z. J. Liu, R. Snyder, A. Soma, T. Shirakawa, B. L. Ziober et al., VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells, Faseb J, issue.13, pp.17-1931, 2003.

N. Maehara, Experimental microcomputed tomography study of the 3D microangioarchitecture of tumors, European Radiology, vol.13, issue.7, pp.1559-65, 2003.
DOI : 10.1007/s00330-002-1729-z

S. P. Massia and J. A. Hubbell, An RGD spacing of 440 nm is sufficient for integrin alpha V beta 3- mediated fibroblast spreading and 140 nm for focal contact and stress fiber formation, The Journal of Cell Biology, vol.114, issue.5, pp.1089-100, 1991.
DOI : 10.1083/jcb.114.5.1089

M. J. Mauro and B. J. Druker, STI571: Targeting BCR-ABL as Therapy for CML, The Oncologist, vol.6, issue.3, pp.233-241, 2001.
DOI : 10.1634/theoncologist.6-3-233

R. Max, R. R. Gerritsen, P. T. Nooijen, S. L. Goodman, A. Sutter et al., Immunohistochemical analysis of integrin alphav beta3 expression on tumor-associated vessels of human carcinomas, Int J Cancer, issue.3, pp.71-320, 1997.

K. P. Mchugh, K. Hodivala-dilke, M. H. Zheng, N. Namba, J. Lam et al., Mice lacking ??3 integrins are osteosclerotic because of dysfunctional osteoclasts, Journal of Clinical Investigation, vol.105, issue.4, pp.433-473, 2000.
DOI : 10.1172/JCI8905

P. Mcquade and L. C. Knight, Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3), Q J Nucl Med, vol.47, issue.3, pp.209-229, 2003.

D. Meitar, S. E. Crawford, A. W. Rademaker, and S. L. Cohn, Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma., Journal of Clinical Oncology, vol.14, issue.2, pp.405-419, 1996.
DOI : 10.1200/JCO.1996.14.2.405

F. Mitjans, T. Meyer, C. Fittschen, S. Goodman, A. Jonczyk et al., In vivo therapy of malignant melanoma by means of antagonists of ??v integrins, International Journal of Cancer, vol.59, issue.5, pp.716-739, 2000.
DOI : 10.1002/1097-0215(20000901)87:5<716::AID-IJC14>3.0.CO;2-R

A. Mitra, J. Mulholland, A. Nan, E. Mcneill, H. Ghandehari et al., Targeting tumor angiogenic vasculature using polymer???RGD conjugates, Journal of Controlled Release, vol.102, issue.1, pp.191-201, 2005.
DOI : 10.1016/j.jconrel.2004.09.023

S. Miyamoto, S. K. Akiyama, and K. M. Yamada, Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function, Science, vol.267, issue.5199, pp.883-888, 1995.
DOI : 10.1126/science.7846531

B. J. Moeller, Y. Cao, Z. Vujaskovic, C. Y. Li, Z. A. Haroon et al., The relationship between hypoxia and angiogenesis, Seminars in Radiation Oncology, vol.14, issue.3, pp.215-236, 2004.
DOI : 10.1016/j.semradonc.2004.04.005

A. M. Montgomery, R. A. Reisfeld, and D. A. Cheresh, Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen., Proceedings of the National Academy of Sciences, vol.91, issue.19, pp.91-8856, 1994.
DOI : 10.1073/pnas.91.19.8856

P. G. Natali, C. V. Hamby, B. Felding-habermann, B. Liang, M. R. Nicotra et al., Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions, Cancer Res, issue.8, pp.57-1554, 1997.

G. R. Nemerow and P. L. Stewart, Role of alpha(v) integrins in adenovirus cell entry and gene delivery, Microbiol Mol Biol Rev, vol.63, issue.3, pp.725-759, 1999.

R. F. Nicosia and E. Bonanno, Inhibition of angiogenesis in vitro by Arg-Gly-Aspcontaining synthetic peptide, Am J Pathol, vol.138, issue.4, pp.829-862, 1991.

J. Nip, H. Shibata, D. J. Loskutoff, D. A. Cheresh, and P. Brodt, Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin., Journal of Clinical Investigation, vol.90, issue.4, pp.1406-1419, 1992.
DOI : 10.1172/JCI116007

M. Ogawa, K. Hatano, S. Oishi, Y. Kawasumi, N. Fujii et al., Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo ??v??3 integrin related tumor imaging, Nuclear Medicine and Biology, vol.30, issue.1, pp.1-9, 2003.
DOI : 10.1016/S0969-8051(02)00387-6

M. Okroj, Z. Dobrzanska-paprocka, K. Rolka, and J. Bigda, In vitro and in vivo analyses of the biological activity of RGD peptides towards Ab Bomirski melanoma, Cell Mol Biol Lett, vol.8, issue.4, pp.873-84, 2003.

O. , R. M. Holmgren, L. Chen, C. Folkman, and J. , Angiostatin induces and sustains dormancy of human primary tumors in mice, Nat Med, vol.2, issue.6, pp.689-92, 1996.

O. , R. M. Boehm, T. Shing, Y. Fukai, N. Vasios et al., Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, pp.277-85, 1997.

T. S. Panetti and P. J. Mckeown-longo, The alpha v beta 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin, J Biol Chem, vol.268, issue.16, pp.11492-11497, 1993.

L. Pardanaud, D. Moyon, and A. Eichmann, L'embryologie des vaisseaux., m??decine/sciences, vol.17, issue.5, pp.543-51, 2001.
DOI : 10.4267/10608/1966

S. Paul and E. Regulier, [Molecular basis of oncogenesis, Ann Biol Clin, vol.59, issue.4, pp.393-402, 2001.

N. Pavlov and J. Badet, [Angiogenin: involvement in angiogenesis and tumour growth], Bull Cancer, vol.88, issue.8, pp.725-757, 2001.

E. Petitclerc, S. Stromblad, T. L. Von-schalscha, F. Mitjans, J. Piulats et al., Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival, Cancer Res, issue.11, pp.59-2724, 1999.

B. J. Pichler, M. Kneilling, R. Haubner, H. Braumuller, M. Schwaiger et al., Imaging of delayed-type hypersensitivity reaction by PET and 18F- galacto-RGD, J Nucl Med, vol.46, issue.1, pp.184-193, 2005.

M. Pierschbacher, E. G. Hayman, and E. Ruoslahti, Synthetic peptide with cell attachment activity of fibronectin., Proceedings of the National Academy of Sciences, vol.80, issue.5, pp.1224-1231, 1983.
DOI : 10.1073/pnas.80.5.1224

M. D. Pierschbacher and E. Ruoslahti, Variants of the cell recognition site of fibronectin that retain attachment-promoting activity., Proceedings of the National Academy of Sciences, vol.81, issue.19, pp.81-5985, 1984.
DOI : 10.1073/pnas.81.19.5985

J. A. Posey, M. B. Khazaeli, A. Delgrosso, M. N. Saleh, C. Y. Lin et al., ) Antibody in Patients with Metastatic Cancer, Cancer Biotherapy & Radiopharmaceuticals, vol.16, issue.2, pp.125-157, 2001.
DOI : 10.1089/108497801300189218

C. W. Pugh and P. J. Ratcliffe, Regulation of angiogenesis by hypoxia: role of the HIF system, Nature Medicine, vol.9, issue.6, pp.677-84, 2003.
DOI : 10.1038/nm0603-677

S. Rafii, D. Lyden, R. Benezra, K. Hattori, and B. Heissig, Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?, Nature Reviews Cancer, vol.91, issue.11, pp.826-861, 2002.
DOI : 10.1038/nrc925

J. Raguse, H. J. Gath, J. Bier, H. Riess, and H. Oettle, Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour, Oral Oncology, vol.40, issue.2, pp.228-258, 2004.
DOI : 10.1016/j.oraloncology.2003.08.003

R. S. Cassara, G. D-'amato, M. Alessandro, R. Pellegrino, M. Degani et al., Cross talk between beta(1) and alpha(V) integrins: beta(1) affects beta(3) mRNA stability, Mol Biol Cell, issue.10, pp.12-3126, 2001.

L. E. Reynolds, L. Wyder, J. C. Lively, D. Taverna, S. D. Robinson et al., Enhanced pathological angiogenesis in mice lacking ??3 integrin or ??3 and ??5 integrins, Nature Medicine, vol.8, issue.1, pp.27-34, 2002.
DOI : 10.1038/nm0102-27

D. Ribatti, The involvement of endothelial progenitor cells in tumor angiogenesis, Journal of Cellular and Molecular Medicine, vol.61, issue.3, pp.294-300, 2004.
DOI : 10.1038/87904

W. Risau and I. Flamme, Vasculogenesis, Annual Review of Cell and Developmental Biology, vol.11, issue.1, pp.73-91, 1995.
DOI : 10.1146/annurev.cb.11.110195.000445

W. Risau, Mechanisms of angiogenesis, Nature, vol.386, issue.6626, pp.671-675, 1997.

R. L. Roberts and P. C. Lin, Structural and Functional Optical Imaging of Angiogenesis in Animal Models, Methods Enzymol, vol.386, pp.105-127, 2004.
DOI : 10.1016/S0076-6879(04)86004-X

S. D. Robinson, L. E. Reynolds, L. Wyder, D. J. Hicklin, and K. M. Hodivala-dilke, Beta3- integrin regulates vascular endothelial growth factor-A-dependent permeability, Arterioscler Thromb Vasc Biol, issue.11, pp.24-2108, 2004.

V. I. Romanov and M. S. Goligorsky, RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro, The Prostate, vol.245, issue.2, pp.108-126, 1999.
DOI : 10.1002/(SICI)1097-0045(19990501)39:2<108::AID-PROS5>3.0.CO;2-9

Y. A. Rovensky, Cellular and molecular mechanisms of tumor invasion, Biochemistry (Mosc), vol.63, issue.9, pp.1029-1072, 1998.

C. Rüegg, Une nouvelle cible pour la thérapeutique anticancéreuse : la vascularisation tumorale, Forum Med Suisse, vol.14, pp.317-323, 2002.

C. Rüegg and A. Mariotti, Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis, Cellular and Molecular Life Sciences, vol.60, issue.6, pp.1135-57, 2003.
DOI : 10.1007/s00018-003-2297-3

E. Ruoslahti, Fibronectin and Its Integrin Receptors in Cancer, Adv Cancer Res, vol.76, pp.1-20, 1999.
DOI : 10.1016/S0065-230X(08)60772-1

P. A. Rupp, A. Czirok, and C. D. Little, alphavbeta3 integrin-dependent endothelial cell dynamics in vivo, pp.2887-97, 2004.

A. A. Sablina, P. M. Chumakov, A. J. Levine, and B. P. Kopnin, p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling, Oncogene, vol.20, issue.8, pp.20-899, 2001.
DOI : 10.1038/sj.onc.1204156

M. Santimaria, G. Moscatelli, G. L. Viale, L. Giovannoni, G. Neri et al., Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer, Clin Cancer Res, vol.9, issue.2, pp.571-580, 2003.

F. A. Scappaticci, Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies, Journal of Clinical Oncology, vol.20, issue.18, pp.3906-3933, 2002.
DOI : 10.1200/JCO.2002.01.033

M. Scatena and C. Giachelli, The ????v????3 Integrin, NF-????B, Osteoprotegerin Endothelial Cell Survival Pathway Potential Role in AngiogenesisTcm, Trends in Cardiovascular Medicine, vol.12, issue.2, pp.83-91, 2002.
DOI : 10.1016/S1050-1738(01)00151-7

M. Schirner, A. Menrad, A. Stephens, T. Frenzel, P. Hauff et al., Molecular Imaging of Tumor Angiogenesis, Annals of the New York Academy of Sciences, vol.22, issue.suppl. 1, pp.67-75, 2004.
DOI : 10.1196/annals.1294.007

S. M. Schoenwaelder and K. Burridge, Bidirectional signaling between the cytoskeleton and integrins, Current Opinion in Cell Biology, vol.11, issue.2, pp.274-86, 1999.
DOI : 10.1016/S0955-0674(99)80037-4

A. J. Schraa, R. J. Kok, A. D. Berendsen, H. E. Moorlag, E. J. Bos et al., Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting, Journal of Controlled Release, vol.83, issue.2, pp.241-51, 2002.
DOI : 10.1016/S0168-3659(02)00206-7

M. A. Schwartz and R. K. Assoian, Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways, J Cell Sci, vol.114, pp.2553-60, 2001.

R. M. Shaheen, D. W. Davis, W. Liu, B. K. Zebrowski, M. R. Wilson et al., Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis, Cancer Res, issue.21, pp.59-5412, 1999.

S. J. Shattil, Function and regulation of the beta 3 integrins in hemostasis and vascular biology, Thromb Haemost, vol.74, issue.1, pp.149-55, 1995.

X. Shen and M. Falzon, Parathyroid hormone-related protein upregulates integrin expression via an intracrine pathway in PC-3 prostate cancer cells" Regul peptides, pp.1-3, 2003.

M. Shimaoka and T. A. Springer, Therapeutic antagonists and conformational regulation of integrin function, Nature Reviews Drug Discovery, vol.2, issue.9, pp.703-719, 2003.
DOI : 10.1038/nrd1174

D. A. Sipkins, D. A. Cheresh, M. R. Kazemi, L. M. Nevin, M. D. Bednarski et al., Detection of tumor angiogenesis in vivo by ??v??3-targeted magnetic resonance imaging, Nature Medicine, vol.10, issue.5, pp.623-629, 1998.
DOI : 10.1016/0092-8674(94)90007-8

S. A. Stacker, M. G. Achen, L. Jussila, M. E. Baldwin, and K. Alitalo, Lymphangiogenesis and cancer metastasis, Nat Rev Cancer, vol.13, issue.8, pp.573-83, 2002.
DOI : 10.1007/978-90-481-2247-9

A. Stopeck, M. Sheldon, M. Vahedian, G. Cropp, R. Gosalia et al., Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies, Clin Cancer Res, vol.8, issue.9, pp.2798-805, 2002.

S. Stromblad, J. C. Becker, M. Yebra, P. C. Brooks, and D. A. Cheresh, Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis., Journal of Clinical Investigation, vol.98, issue.2, pp.98-426, 1996.
DOI : 10.1172/JCI118808

D. G. Stupack, X. S. Puente, S. Boutsaboualoy, C. M. Storgard, and D. A. Cheresh, Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins, The Journal of Cell Biology, vol.85, issue.3, pp.459-70, 2001.
DOI : 10.1074/jbc.272.12.7797

D. G. Stupack and D. A. Cheresh, Get a ligand, get a life: integrins, signaling and cell survival, Journal of Cell Science, vol.115, issue.19, pp.3729-3767, 2002.
DOI : 10.1242/jcs.00071

D. G. Stupack and D. A. Cheresh, Integrins and Angiogenesis, Curr Top Dev Biol, vol.64, pp.207-245, 2004.
DOI : 10.1016/S0070-2153(04)64009-9

J. Takagi, Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins, Biochemical Society Transactions, vol.32, issue.3, pp.403-409, 2004.
DOI : 10.1042/bst0320403

Y. Takebayashi, S. Aklyama, K. Yamada, S. Akiba, and T. Aikou, Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma, Cancer, vol.92, issue.2, pp.226-257, 1996.
DOI : 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J

T. Tarui, L. A. Miles, and Y. Takada, Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells, J Biol Chem, issue.43, pp.276-39562, 2001.

K. Temming, R. M. Schiffelers, G. Molema, and R. J. Kok, RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature, Drug Resistance Updates, vol.8, issue.6, 2005.
DOI : 10.1016/j.drup.2005.10.002

G. C. Tucker, Alpha v integrin inhibitors and cancer therapy, Curr Opin Investig Drugs, vol.4, issue.6, pp.722-753, 2003.

M. Valesky, A. J. Spang, G. W. Fisher, D. L. Farkas, and D. Becker, Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis, Mol Med, vol.8, issue.2, pp.103-115, 2002.

R. L. Van-leeuwen, I. G. Yoshinaga, T. Akasaka, S. K. Dekker, B. J. Vermeer et al., Attachment, spreading and migration of melanoma cells on vitronectin. The role of alphavbeta3 and alphavbeta5 integrins, Experimental Dermatology, vol.24, issue.6, pp.308-323, 1996.
DOI : 10.1083/jcb.110.6.2175

G. P. Van-nieuw-amerongen, P. Koolwijk, A. Versteilen, and V. W. Van-hinsbergh, Involvement of RhoA/Rho Kinase Signaling in VEGF-Induced Endothelial Cell Migration and Angiogenesis In Vitro, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.2, pp.211-218, 2003.
DOI : 10.1161/01.ATV.0000054198.68894.88

A. L. Vavere and J. S. Lewis, Imaging the effects of anti-angiogenic treatments, Q J Nucl Med, vol.47, issue.3, pp.163-70, 2003.

E. Vicaut, [Principal characteristics of tumor microcirculation revealed by experimental techniques in vivo], pp.483-94, 2001.

A. Vonlaufen, G. Wiedle, B. Borisch, S. Birrer, P. Luder et al., Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival, Mod Pathol, issue.11, pp.14-1126, 2001.

N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman, Tumor Angiogenesis and Metastasis ??? Correlation in Invasive Breast Carcinoma, New England Journal of Medicine, vol.324, issue.1, pp.1-8, 1991.
DOI : 10.1056/NEJM199101033240101

S. A. Wickström, K. Alitalo, and J. Keski-oja, Endostatin Associates with Lipid Rafts and Induces Reorganization of the Actin Cytoskeleton via Down-regulation of RhoA Activity, Journal of Biological Chemistry, vol.278, issue.39, pp.278-37895, 2003.
DOI : 10.1074/jbc.M303569200

S. A. Wickström, K. Alitalo, and J. Keski-oja, An Endostatin-derived Peptide Interacts with Integrins and Regulates Actin Cytoskeleton and Migration of Endothelial Cells, Journal of Biological Chemistry, vol.279, issue.19, pp.279-20178, 2004.
DOI : 10.1074/jbc.M312921200

C. H. Williams, T. Kajander, T. Hyypia, T. Jackson, D. Sheppard et al., Integrin alpha v beta 6 is an RGD-dependent receptor for coxsackievirus A9, J Virol, issue.13, pp.78-6967, 2004.

C. Wittekindt, M. Bottger, H. D. Holtje, M. Schafer-korting, R. Cartier et al., Integrin specificity of the cyclic Arg-Gly-Asp motif and its role in integrin-targeted gene transfer, Biotechnol Appl Biochem, pp.40-281, 2004.

Y. Wu, X. Zhang, Z. Xiong, Z. Cheng, D. R. Fisher et al., microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu- labeled tetrameric RGD peptide, J Nucl Med, issue.10, pp.46-1707, 2005.

J. P. Xiong, T. Stehle, R. Zhang, A. Joachimiak, M. Frech et al., Crystal structure of the extracellular segment of integrin alphaV beta3 in complex with an Arg-Gly-Asp ligand, Science, issue.5565, pp.296-151, 2002.

J. T. Yang, H. Rayburn, and R. O. Hynes, Embryonic mesodermal defects in alpha 5 integrin-deficient mice, pp.1093-105, 1993.

D. Zagzag, A. Hooper, D. R. Friedlander, W. Chan, J. Holash et al., In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis, Experimental Neurology, vol.159, issue.2, pp.391-400, 1999.
DOI : 10.1006/exnr.1999.7162